ArticleCell reports. Medicine2026

AAV-based gene therapy with modified HEXB confers lasting therapeutic benefits in GM2 gangliosidosis models.

Keisuke Kitakaze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.